Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 16, 2016International Journal of StrokeOpen Access

Animal models show GPVI inhibition abolishes platelet response to collagen and reduces platelet aggregation, resulting in smaller arterial thrombi, suggesting potential for a bleeding-free antiplatelet therapy in humans.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does Glycoprotein VI (GPVI) inhibition reduce arterial thrombosis without increasing bleeding risk compared to current antiplatelet therapy?

Population

Patients at risk of ischemic stroke and animal models of arterial thrombosis

Comparison

Glycoprotein VI (GPVI) inhibition vs Current antiplatelet therapy

Design

Review

Authors

IIIsuru InduruwaSJStéphanie JungEWElizabeth A. Warburton

Discussion

Loading...

Member takes

Overview

Targeting GPVI may enable safer antithrombotic strategies in stroke; leaves open confirmation via dedicated clinical trials.

Structured PICO

Does Glycoprotein VI (GPVI) inhibition reduce arterial thrombosis without increasing bleeding risk compared to current antiplatelet therapy?

P
Population
Patients at risk of ischemic stroke and animal models of arterial thrombosis
I
Intervention
Glycoprotein VI (GPVI) inhibition
C
Comparator
Current antiplatelet therapy
O
Outcome
Arterial thrombus formation and bleeding risk

GPVI inhibition is a promising therapeutic strategy for ischemic stroke that may prevent arterial thrombosis without the systemic bleeding risks of current antiplatelet agents.

Cite This Study

Induruwa et al. (2016) studied this question.

synapsesocial.com/papers/6a70209f5671bbf00bc2a695https://doi.org/10.1177/1747493016654532
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Research advances on platelet glycoprotein VI in ischemic stroke2026
  2. 2Platelets and Arterial Thrombosis: Evolving Role of Platelet Gpvi as an Antithrombotic Drug Target2014 · 1 citations
  3. 3GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease2024 · 24 citations
  4. 4From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks2019 · 28 citations
  5. 5Glycoprotein VI interplay with fibrin(ogen) in thrombosis2023 · 32 citations